Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R. Lewis, Michael Millward, Sally Lord, Richard J. Gralla, James C.H. Yang, Tony Mok, Chee K. Lee

Research output: Contribution to journalReview article

Abstract

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

Original languageEnglish (US)
Pages (from-to)2371-2383
Number of pages13
JournalFuture Oncology
Volume15
Issue number20
DOIs
Publication statusPublished - Jul 2019

    Fingerprint

Keywords

  • PD-L1 expression
  • chemoimmunotherapy
  • meta-analysis
  • non-small-cell lung cancer
  • progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C. R., ... Lee, C. K. (2019). Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 15(20), 2371-2383. https://doi.org/10.2217/fon-2019-0105